Skip to main content
ClinicalTrials.govrestricted

Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients

ClinicalTrials.gov study NCT02330783. IPD Sharing: Not stated. Countries: 1. Publications: 4.

ShareScore

32/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
12
Access
0
Reuse readiness
0
Engagement
8

Topics

Dataset details

Repository
ClinicalTrials.gov
Published
February 11, 2026
License
IPD-UNDECIDED
DOI
clinicaltrials.gov/NCT02330783

Scored with release 0.9.0

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.